Afsar Shaik

Afsar Shaik

Auto-generated profile, based on publicly available information

Afsar Shaik

Faculty of Health Sciences, Villa College, Rah Dhebai Hingun 20373, Male', Maldives

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2017 in Journal of Complementary and Alternative Medical Research
Verified
Journal Article
Open access
PDF file
ASAfsar Shaik
Afsar Shaik
PYPrasanna Raju Yalavarthi
Prasanna Raju Yalavarthi
CBChandrasekhar Kothapalli Bannoth
Chandrasekhar Kothapalli Bannoth
Aim and Objective: The aim of this review was to provide a detailed concept to the researchers on antifertility activity of several plants inhibiting male and female fertility and may be developed into contraceptives. Despite of many medicinal plants have been claimed to prevent fertility, only few plants were so far been investigated for their antifertility activity. Materials and Methods: An extensive bibliographic investigation was carried out by analyzing various classical text books, scientific journals, consulting worldwide accepted databases for providing suitable information on antifertility medicinal plants. Plant species traditionally used as contraceptives, abortifacients, emmenagogues, spermatogenics were considered as antifertility agents. Results: Overall 233 plant species belonging to various families, traditionally used as antifertility agents in both males and females has been incorporated in this review. The various plant parts used in fertility regulation includes leaves, fruits, roots, bark, stem etc. Conclusion: In conclusion, it is clear that medicinal plants play an important role as antifertility agents. Despite of various commercially available oral contraceptives in the market, herbal antifertility agents shows promising output by minimizing the number of adverse drug properties. Current research towards traditional medicine is growing rapidly because of its safety and less cost consumption.

1 April 2018 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
VJVenu Gopal Jonnalagadda
Venu Gopal Jonnalagadda
ASAfsar Shaik
Afsar Shaik
Statin on insulin and adiponectin levels: true or false prophecy? Venu Gopal Jonnalagadda,1 Afsar Shaik2 1Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research, Bhangagarh, Guwahati, Assam, India; 2Department of Pharmacology, Narayana Pharmacy College, Chinthareddy Palem, Nellore, Andhra Pradesh, IndiaWe read the article “Effect of different doses of statins on the development of type 2 diabetes mellitus in patients with myocardial infarction” by Gruzdeva et al1 with interest. The authors conducted a prospective cohort study on patients with diagnosed myocardial infarction who were on different doses of atorvastatin, ie, 20 mg/d or 40 mg/d, for new onset of diabetes for a duration of 12 months.Authors’ replyEvgenya Uchasova, Olga GruzdevaFederal State Budgetary Institution, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian FederationWe would like to thank Venu Gopal Jonnalagadda and Afsar Shaik for the letter in response to our article.1 Yes, indeed in our study, statins at a dose of 20 and 40 mg/mL, at 20 mg/d atorvastatin, were observed to improve the sensitivity to insulin and eliminate adipokine imbalance and ghrelin deficiency. At a dose of 40 mg/d, atorvastatin showed increased negative effects, such as a reduction in insulin secretion, hyperglycemia, impaired glucose tolerance, high levels of leptin, ghrelin deficiency, and manifestation of type 2 diabetes mellitus. Statins at a dose of 80 mg/mL were not included in this work; however, at this dose in this study, we observed a decrease in levels of adiponectin and insulin.1View the original paper by Gruzdeva and colleagues.

1 July 2024 in Future Journal of Pharmaceuticals and Health Sciences
Verified
Journal Article
Open access
PDF file
ASAfsar Shaik
Afsar Shaik
FMFazeen Mohamed
Fazeen Mohamed
The treatment of chronic diseases poses significant challenges to healthcare systems worldwide. While conventional medical approaches have made substantial progress, alternative medicines have gained recognition for their potential to complement or even su bstitute conventional treatments. This comprehensive review examines the role of alternative medications in chronic disease management, encompassing a wide range of modalities, from herbal remedies and acupuncture to mind - body therapies and chiropractic ca re. We explore the efficacy and safety of alternative treatments, mechanisms of action, patient perspectives, regulatory and ethical considerations, cost - effectiveness, and the potential for integration with conventional medicine. Drawing upon clinical stu dies, patient testimonials, and scholarly sources, this review highlights alternative medicine's diverse and evolving landscape, its significance in improving patient outcomes, and the challenges that must be addressed. We offer recommendations for patient s, healthcare providers, and policymakers on integrating and responsible use of alternative medicines in chronic disease management.

10 July 2025
Verified
Book Chapter
Closed access
PDF file
TBTalamanchi Balakrishna
Talamanchi Balakrishna
RPRaveesha Peeriga
Raveesha Peeriga
Krishnaveni ManuboluKrishnaveni Manubolu
Krishnaveni Manubolu
KLKNV CHENCHU LAKSHMI
KNV CHENCHU LAKSHMI
MPMiriyala Preethika
Miriyala Preethika
ASAfsar Shaik
Afsar Shaik
In this chapter, we summarize recent progress in drug discovery and assess its implications for future research and development. The final section summarizes recent key findings from high-throughput screening (HTS), biomarker identification and personalized medicine. Moreover, it identifies the challenges encountered, like high costs, extended development cycles and both regulatory and commercial hurdles. Emerging trends in drug discovery, such as artificial intelligence (AI), genomic integration, and new therapeutic modalities, are explored as future prospects. By highlighting the successes, the challenges that persist, and the innovations that might alter the face of drug development, this analysis covers the full version of the progress to date. Results highlight a need for sustained interdisciplinary partnerships and continued investment in state-of-the-art technologies to overcome current constraints and progress discovery toward new, effective therapies. <!----> <!----> <!----> <!---->

29 October 2026 in Journal of Natural Remedies
Verified
Journal Article
Closed access
ASAfsar Shaik
Afsar Shaik
RPRaveesha Peeriga
Raveesha Peeriga
VTVeera Thota
Veera Thota
PKPRASHANTH KUMAR KATTA
PRASHANTH KUMAR KATTA
NJNuraddeen Ibrahim Jaafar
Nuraddeen Ibrahim Jaafar
Background: Although there are limitations and potential side effects with current methods of contraception, male contraception is an important field of reproductive health research. The medicinal plants have inherent bio-active phytochemical constituents and biological activities which have captured the scientific interest as potential natural male anti-fertility agents. Aim: The current research will compile and assess medicinal plants that have been reported to have male antifertility activity in a systematic manner. Methodsmprehensive literature review. The inclusion criteria were relevant studies that were published between 1980 and 2025. Results and Discussion: A total of 233 medicinal plant species with reported antifertility activity were identified, of which 100 plants exhibiting experimentally validated male antifertility effects were selected for detailed evaluation. It was found that antifertility effects of medicinal plants occur in various ways, such as inhibition of spermatogenesis, hormonal effects, antiandrogenic effects, etc. Families of plants including Fabaceae, Asteraceae, Apocynaceae and Lamiaceae were highly represented. Plant parts that were most used were seeds, roots, and leaves, meaning that concentrations of bioactive phytoconstituents were high. One of the greatest limitations found was the absence of clinical literature and standardisation of plant extracts. Conclusion: Medicinal plants are a potentially rich and untapped source of male contraceptive agents. Nevertheless, additional studies that entail isolation of active compounds, mechanistic validation, safety assessment, and clinical trials are necessary to ensure their successful translation into viable contraceptive solutions. Major Findings: A total of 233 species were identified as medicinal plants and 100 plants with experimentally reported male antifertility activity were investigated in detail. The main mechanisms involved were inhibition of spermatogenesis, hormonal modulation, antiandrogenic effect, decreased sperm motility, and testicular changes. The limited clinical evidence, lack of standardised plant extracts, and uncertainty about safety and reversibility underscore the need for more mechanistic studies and clinical trials to be conducted.